Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Market Cap	1.11B -46.6%
Revenue (ttm)	1.50B -0.5%
Net Income	161.05M +13.0%
EPS	0.66 +5.2%
Shares Out	240.03M
PE Ratio	6.99
Forward PE	n/a
Dividend	0.07 (1.42%)
Ex-Dividend Date	Jun 17, 2026

Volume	27,000
Open	5.050
Previous Close	5.050
Day's Range	4.480 - 5.050
52-Week Range	4.500 - 10.840
Beta	1.35
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About HKG:2566

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,787
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2566

Financial Performance

In 2025, HKG:2566's revenue was 1.31 billion, a decrease of -4.59% compared to the previous year's 1.37 billion. Earnings were 138.41 million, a decrease of -0.14%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error